Browsing by Subject "Registry"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Open Access
    Clinical subtypes in breast cancer patients with brain metastases from an ambispective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM)
    (2026-02-20) López Tarruella, Sara ; Guerrero-Zotano, Ángel ; Antolín, Silvia ; Cruz, Josefina ; Martínez, Purificación ; Rodríguez, César A.; Falo, Catalina ; Rodríguez Lescure, Álvaro ; Adrover, Encarna ; Hernández, María ; Andrés, Raquel ; Chacón, José Ignacio ; Alonso Romero, José Luis; Miguel, Ana ; Gómez Raposo, César ; Margelí, Mireia ; González, Iria ; Guerra, José Antonio; Antón, Antonio ; Tibau, Ariadna ; Miralles, Juan José; Escudero, María José; Bezares, Susana ; Rojo, Federico ; Álvarez, Isabel ; Medicina Interna; Facultades de la UMU::Facultad de Medicina
    Background: Breast cancer frequently results in brain metastases (BCBM), leading to poor outcomes. Central nervous system (CNS) involvement entails significant challenges in advanced breast cancer (ABC) patients. Objectives: To characterize BCBM patients according to surrogate clinical BC subtypes and evaluate the interval between ABC and BCBM detection, both at ABC diagnosis (BCBM1 cohort) and for those who develop BCBM subsequently (BCBM2 cohort). Secondary objectives included analyzing the time-related outcomes by BC subtype. Design: RegistEM is an ongoing ambispective, observational study of ABC patients diagnosed since January/2016. Methods: We describe the characteristics of BCBM patients reported by January 22, 2024, categorized by BC subtype on the most recent tumor sample obtained before first-line therapy. Results: At the cutoff date, 346/1947 (18%) patients diagnosed with ABC between January/2016 and December/2019 developed BCBM, and 288/346 (83%) died. All patients were female, predominantly Caucasian (98%), with a median age of 55 years at ABC diagnosis. The distribution by subtype was 170/346 (49%) HR+/HER2−, 68/346 (20%) HR+/HER2+, 54/346 (16%) HR−/HER2+, and 51/346 (15%) HR−/HER2− (triple negative (TN)). One-fourth (85/346) were in the BCBM1 cohort, with 22/85 (26%) having BCBM as the only metastatic location; in this cohort, median time to BCBM was 38 months, with shorter intervals in HR−/HER2+ and TN subtypes (17 and 18 months, respectively). In the BCBM2 cohort (261/346), the median time to BCBM was 24 months, with the shortest interval in TN (13 months). Median survival from BCBM diagnosis was 26 months (95% confidence interval (CI), 20−35) in BCBM1 and 9 months (95% CI, 7−12) in BCBM2 (hazard ratio, 2.3; 95% CI, 1.7−3.0); TN subtype showed the poorest results (median of 6 months; 95% CI, 3−13). Conclusion: TN and HER2+ BC subtypes progressed faster to BCBM and had worse outcomes. Survival differed significantly between the two cohorts, BCBM1 and BCBM2. Continued research is essential to improve the treatment and prevention strategies.
  • Thumbnail Image
    Publication
    Open Access
    ¿El futuro es de generado? Aportes para pensar en una sociedad sin encasillamientos de sexo/género
    (Universidad de Murcia, Servicio de Publicaciones, 2022) Grinstein, Victoria
    Este artículotiene como finalidad poner en discusión la categoría “sexo” presente en el documento nacional de identificación argentino. A partir de los aportes de la teoría queer y trans, se propone pensar los alcances posibles de modificar o eliminar esta categoría, en pos de crear una sociedad que se libere de los encasillamientos de género en términos registrales. Tomando distintas interpretaciones, se discute en torno a la construcción de la identidad a partir de la sanción de la Ley de Identidad de Géneroen el año 2012, sus alcances y limitaciones y las posibles implicancias sociales de pensarnos por fuera de la forma binariaque tenemos actualmente para categorizarnos. Para ello se utilizan los casos de varias personas travestis y no binaries en Argentina que lograron hacer cambios registrales para que en el casillero de “sexo” no aparezca ni hombre ni mujer.